Tag: <span>Interim Analysis</span>

Home / Interim Analysis
Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released
Post

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725 requires only a single injection and can be stored in a refrigerator for months....